Feng Guo

Feng Guo is the current CEO of Genor BioPharma. Prior to this, they served as group vice president and CEO of Xuanzhu Biopharm from May 2017 to April 2020. In this role, they were responsible for heading up Merck's R&D efforts in Beijing, including both new drug development and registration, as well as the LCM for all marketed products.

Feng has also served on several leadership teams at Merck, including the Asia Pacific Regional Leadership team and the China Country Leadership team. In addition, they were a member of the Joint Advisory Committee of the Merck-BeiGene partnership.

Throughout their career, Feng Guo has been a strong advocate for R&D within China, and has established collaborations with leading academic institutions and medical associations, NGOs, local biotech/pharmas, and CROs. Feng has also built a strong working relationship with regulators and investigators.

Feng Guo has a PhD in clinical pharmacology from the University of Toronto, an MSc from the University of Waterloo, and a BSc from Sun Yat-sen University.

Some direct reports include Steven Kan - Chief Technology Officer, Li Tong - Chief Medical Officer, and Joe Zhou - President.